Unified Health System
Conditions
Interventions
These are experimental trials, divided into two phases: phase 1 will be a quasi-experimental intervention study (with pharmacists participating in the training)
phase 2 will be a two-arm, open-label, randomized clinical trial. Phase 1: pharmacists who work in Primary Health Care in the municipalities concerned (it has already been agreed with the management)
conceptual and historical aspects of Clinical Pharmacy and classification of problems related to pharmacotherapy (meeting 2)
evidence-based practices and general aspects of Diabetes Mellitus (meeting 3)
oral antidiabetics and insulin therapy in type 2 Diabetes Mellitus (meeting 4)
clinical management of Systemic Arterial Hypertension (SAH) and Heart Failure (HF) in patients with Diabetes Mellitus (meeting 5)
dyslipidemia and Diabetes Mellitus, pharmacotherapy of Type 1 Diabetes Mellitus and Gestational Diabetes Mellitus (meeting 6)
Diabetes Mellitus in geriatrics, Diabetes Mellitus and Chronic Kidney Disease (meeting 7)
diabetic foot care
non-drug treatment, physical exercises and diet in Diabetes Mellitus (meeting 8). In phase 2 (RCT), a minimum sample of 702 patients was estimated. For this, the following pa
N02.421.726.407
V03.175.250.500.500
N02.421.585
Sponsors
Universidade Federal de São João del-Rei (UFSJ)
Universidade Federal de São João del-Rei (UFSJ)
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: In the first phase, pharmacists who work in Primary Health Care of the Unified Health System of the participating municipalities will be included. There are no exclusion criteria at this stage. In the second phase, patients aged 18 years or older with type I Diabetes Mellitus will be included; or type II; or gestational; or adult latent autoimmune diabetes, known as the LADA type; or Maturity Onset Diabetes of the Young MODY; and who are using at least one drug for the treatment of Diabetes Mellitus
Exclusion criteria
Exclusion criteria: Second phase: patients who are not responsible for their own pharmacotherapy and who do not have a caregiver to accompany them to consultations
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Check whether there was a reduction in glycated hemoglobin in the eight-month period (one visit per month) of patients in the intervention group compared to the control group (and whether such a reduction is statistically significant), by requesting tests. | — |
Secondary
| Measure | Time frame |
|---|---|
| Assess the quality of life before and after the intervention using The World Health Organization Quality of Life assessment, in its abbreviated form (WHOQOL-bref). ;Assess adherence to treatment before and after the intervention using the Morisky-Green test.;Count and describe the interventions performed by pharmacists.;Know the main types of pharmacotherapeutic problems. | — |
Countries
Brazil
Contacts
Public ContactLuanna da Silva
Universidade Federal de São João del-Rei (UFSJ)
Outcome results
None listed